drugset / Trial / NCT01050543

Comparison of Sugammadex With Neostigmine as Reversal Agents for Rocuronium at Reappearance of T2 (Study P06101)

NCT01050543

Phase 3 Completed 128 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupSingle-blindTreatment

Summary

This is a randomized, active-controlled, parallel-group, single-dose, multi-site, safety-assessor blinded study comparing sugammadex to neostigmine for reversal of neuromuscular blockade in Korean subjects undergoing elective surgical procedures under general anesthesia that require rocuronium for neuromuscular blockade. Study medication will be administered at reappearance of T2. Time to recovery will be measured from start of study medication administration to recovery of the T4/T1 ratio of 0.9. The primary hypothesis is that the time to recovery of the T4/T1 ratio of 0.9 is shorter with sugammadex than with neostigmine.

Timeline

Start
2010-02-01
Primary completion
2010-08-20
Completion
2010-08-20

Drugs

EvaluationDrugModalityDoseRoute
Comparator Neostigmine Other / unclassified 50 ug/kg Intravenous
Subject Sugammadex Other / unclassified 2 mg/kg Intravenous
Background Glycopyrrolate Small molecule 10 ug/kg Intravenous

Indications

No indication recorded.